5-Methyl 2,2,4-trimethylpentanedioate | 34601-13-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-Methyl 2,2,4-trimethylpentanedioate
• 英文别名: 5-methoxy-2,2,4-trimethyl-5-oxopentanoic acid
• CAS: 34601-13-3
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: MJFUIOSAJCYVQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲基丙烯酸甲酯 、 异丁酸 生成 5-Methyl 2,2,4-trimethylpentanedioate
  参考文献：
  名称：

  Reactions of dianions of carboxylic acids with esters and .alpha.,.beta.-unsaturated esters, nitriles, and aldehydes

  摘要：

  DOI：

  10.1021/ja00752a084

文献信息

• Oral formulations of bipolar trans carotenoids
  申请人：Diffusion Pharmaceuticals, LLC

  公开号：US10016384B2

  公开（公告）日：2018-07-10

  The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.

  本发明涉及双极反式类胡萝卜素的各种制剂，包括用于口服双极反式类胡萝卜素的药物组合物，其中包括 i) 双极反式类胡萝卜素，ii) 环糊精和 iii) 包衣。本发明还涉及此类制剂的制备及其用途。
• Oral drug dosage forms having desired drug release profiles and uses thereof
  申请人：Triastek, Inc.

  公开号：US10258575B2

  公开（公告）日：2019-04-16

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• Tablets comprising GLP-1 agonist and enteric coating
  申请人：Novo Nordisk A/S

  公开号：US10265384B2

  公开（公告）日：2019-04-23

  The present invention relates to solid pharmaceutical compositions for oral administration comprising a GLP-1 agonist, an absorption enhancer which is a salt of medium-chain fatty acid, and an enteric coating as well as uses thereof.

  本发明涉及由 GLP-1 激动剂、中链脂肪酸盐吸收促进剂和肠溶包衣组成的口服固体药物组合物及其用途。
• Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
  申请人：Impax Laboratories, Inc.

  公开号：US10292935B2

  公开（公告）日：2019-05-21

  The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

  本发明提供了一种控释口服固体制剂，包括：(a) 由左旋多巴和/或左旋多巴酯或其盐组成的核芯控释成分，其中核芯包覆一层粘液黏附聚合物，外包覆一层肠衣聚合物；(b) 脱羧酶抑制剂成分。
• Compartmented pharmaceutical dosage forms
  申请人：Triastek, Inc.

  公开号：US10363220B2

  公开（公告）日：2019-07-30

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。